A recent systematic review, published in the International Journal of Chronic Diseases, revealed the prevalence of the central nervous system (CNS) involvement — rather than the peripheral nervous system (PNS) — in connective tissue disorders like systemic lupus erythematosus. But more research is needed to understand whether these CNS…
According to a new study by physicians at Loyola University Medical Center, diseases such as lupus that cause rashes and other skin conditions can also trigger severe neurological problems — ranging from migraine headaches to double vision and epileptic seizures to strokes. The study, titled “Acquired Neurocutaneous Disorders,” was published…
Neovacs recently announced that it has signed an exclusive licensing contract granting Chong Kun Dang (CKD) Pharmaceutical Corp. of Seoul the right to market IFNα-Kinoïd, Neovacs’ anti-interferon alpha (IFNα) therapeutic vaccine being developed for the treatment of systemic lupus erythematosus (SLE), in South Korea. Lupus is considered an orphan disease in South…
ImmunArray, a molecular diagnostics company developing blood-based tests to support the diagnosis and management of acute and chronic immune and neurodegenerative diseases, has announced that it is making its “rule-out” test for systemic lupus erythematosus (SLE) available throughout the United States. The company’s SLE-key Rule-Out Test® is a cost-effective blood test…
The “Moving Forward Together to Fight Lupus” gala dinner celebrated the upcoming merging of the Alliance for Lupus Research (ALR), the Lupus Research Institute (LRI), and S.L.E. Lupus Foundation. The event — the world’s leading lupus fundraiser — collected close to $3 million for groundbreaking research that promises to…
More than 3,000 scientific abstracts spanning the latest in lupus research were presented at the recent American College of Rheumatology (ACR) annual meeting in San Francisco, which brought together nearly 17,000 healthcare providers and researchers in the fields of rheumatology and immunology. According to an article written by Anita Roach, MS, manager…
Delazatide may be effective to control flares in lupus nephritis patients, according to recent data from The Alliance for Children’s Therapeutics (ACT), a pediatric research collaboration between Seattle Children’s Research Institute and the biotech company Kineta, Inc. The results were presented during the recent American College of Rheumatology Annual Meeting in San Francisco,…
The Lupus Foundation of America presented two awards recognizing distinguished career achievements in lupus research to Dr Mariana J. Kaplan, of the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health (NIH), and Dr Timothy B. Niewold, of the Mayo Clinic, at a Nov. 8 foundation ceremony…
A recent study conducted by researchers at the Hospital for Special Surgery evaluated the Patient Reported Outcomes Measurement Information System (PROMIS) in lupus patients, concluding that the survey could also be used to assess subjective patient experiences. Researchers also reported a disconnect between the patient point of view and objective symptoms, emphasizing the need to…
Hutchison China MediTech Limited (Chi-Med) recently announced that its R&D subsidiary Hutchison MediPharma (HMP) has completed its Phase I study of HMPL-523, a potential global first-in-class oral inhibitor targeting the spleen tyrosine kinase Syk, a key protein involved in B-cell signaling. Modulation of the B-cell signaling pathway has proven to significantly advance…